|
Poly Medicure Limited (polymed.ns) DCF -Bewertung |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Poly Medicure Limited (POLYMED.NS) Bundle
Gewinnen Sie einen Einblick in Ihre Bewertungsanalyse für Poly Medica-Limited (polymedns) unter Verwendung unseres hochmodernen DCF-Taschenrechners! Diese Excel -Vorlage wird mit realen (polymedns) Daten vorinstalliert, sodass Sie Vorhersagen und Annahmen für eine genaue Berechnung des inneren Werts von Poly Medicure Limited anpassen können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2021 |
AY2 2022 |
AY3 2023 |
AY4 2024 |
AY5 2025 |
FY1 2026 |
FY2 2027 |
FY3 2028 |
FY4 2029 |
FY5 2030 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,750.4 | 9,168.9 | 11,152.3 | 13,758.0 | 16,698.3 | 20,233.0 | 24,515.9 | 29,705.3 | 35,993.3 | 43,612.3 |
| Revenue Growth, % | 0 | 18.3 | 21.63 | 23.36 | 21.37 | 21.17 | 21.17 | 21.17 | 21.17 | 21.17 |
| EBITDA | 2,332.7 | 2,524.1 | 3,008.8 | 4,187.0 | 4,533.9 | 5,753.9 | 6,971.9 | 8,447.7 | 10,235.8 | 12,402.6 |
| EBITDA, % | 30.1 | 27.53 | 26.98 | 30.43 | 27.15 | 28.44 | 28.44 | 28.44 | 28.44 | 28.44 |
| Depreciation | 474.4 | 538.7 | 571.2 | 639.1 | 831.8 | 1,082.3 | 1,311.4 | 1,589.0 | 1,925.3 | 2,332.9 |
| Depreciation, % | 6.12 | 5.88 | 5.12 | 4.65 | 4.98 | 5.35 | 5.35 | 5.35 | 5.35 | 5.35 |
| EBIT | 1,858.3 | 1,985.3 | 2,437.6 | 3,547.9 | 3,702.0 | 4,671.6 | 5,660.5 | 6,858.7 | 8,310.5 | 10,069.7 |
| EBIT, % | 23.98 | 21.65 | 21.86 | 25.79 | 22.17 | 23.09 | 23.09 | 23.09 | 23.09 | 23.09 |
| Total Cash | 3,742.7 | 3,516.7 | 3,090.3 | 2,859.9 | 12,079.6 | 8,396.0 | 10,173.2 | 12,326.7 | 14,935.9 | 18,097.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,558.6 | 2,066.3 | 2,354.3 | 2,699.4 | 3,497.3 | 4,221.5 | 5,115.1 | 6,197.8 | 7,509.8 | 9,099.4 |
| Account Receivables, % | 20.11 | 22.54 | 21.11 | 19.62 | 20.94 | 20.86 | 20.86 | 20.86 | 20.86 | 20.86 |
| Inventories | 1,264.8 | 1,683.6 | 2,086.5 | 2,210.3 | 2,855.7 | 3,502.7 | 4,244.1 | 5,142.5 | 6,231.1 | 7,550.1 |
| Inventories, % | 16.32 | 18.36 | 18.71 | 16.07 | 17.1 | 17.31 | 17.31 | 17.31 | 17.31 | 17.31 |
| Accounts Payable | 645.2 | 890.4 | 923.1 | 956.0 | 864.2 | 1,555.4 | 1,884.6 | 2,283.6 | 2,767.0 | 3,352.7 |
| Accounts Payable, % | 8.32 | 9.71 | 8.28 | 6.95 | 5.18 | 7.69 | 7.69 | 7.69 | 7.69 | 7.69 |
| Capital Expenditure | -951.3 | -1,555.8 | -2,392.7 | -2,770.2 | -3,310.3 | -3,668.5 | -4,445.0 | -5,386.0 | -6,526.0 | -7,907.5 |
| Capital Expenditure, % | -12.27 | -16.97 | -21.46 | -20.13 | -19.82 | -18.13 | -18.13 | -18.13 | -18.13 | -18.13 |
| Tax Rate, % | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 |
| EBITAT | 1,402.3 | 1,489.7 | 1,840.1 | 2,661.5 | 2,769.7 | 3,511.4 | 4,254.7 | 5,155.3 | 6,246.6 | 7,568.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,252.8 | -208.6 | -639.6 | 94.5 | -1,243.8 | 245.3 | -184.8 | -223.9 | -271.3 | -328.7 |
| WACC, % | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -616.1 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -342 | |||||||||
| Terminal Value | -48,380 | |||||||||
| Present Terminal Value | -38,441 | |||||||||
| Enterprise Value | -39,057 | |||||||||
| Net Debt | 289 | |||||||||
| Equity Value | -39,346 | |||||||||
| Diluted Shares Outstanding, MM | 99 | |||||||||
| Equity Value Per Share | -396.41 |
What You Will Receive
- Actual POLYMEDNS Financial Data: Pre-loaded with Poly Medicure Limited’s historical and forecasted data for accurate analysis.
- Completely Customizable Template: Effortlessly adjust key inputs such as revenue growth, WACC, and EBITDA percentage.
- Real-Time Calculations: Instantly view updates to Poly Medicure Limited’s intrinsic value as you make changes.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF results.
- Intuitive Design: Easy-to-follow layout and straightforward instructions suitable for all experience levels.
Core Highlights
- Authentic POLYMEDNS Data: Pre-loaded with Poly Medicure's historical financial statistics and future growth projections.
- Completely Customizable Parameters: Modify revenue growth rates, profit margins, cost of capital, tax percentages, and capital expenditures.
- Interactive Valuation Framework: Automatic recalculations of Net Present Value (NPV) and intrinsic value in response to your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to explore different valuation possibilities.
- Intuitive Interface: Streamlined, organized, and suitable for both seasoned professionals and newcomers.
How It Works
- Step 1: Download the Excel file for Poly Medicure Limited (POLYMEDNS).
- Step 2: Examine the pre-filled financial data and forecasts specific to Poly Medicure.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and utilize the findings for your investment strategies.
Reasons to Choose Poly Medicure Limited (POLYMEDNS) Calculator
- Precision: Utilizes real financial data from Poly Medicure Limited for optimal accuracy.
- Adaptability: Allows users to experiment with and adjust inputs as needed.
- Efficiency: Eliminate the complexities of creating a DCF model from the ground up.
- High-Quality Standards: Crafted with the expertise and precision expected at the CFO level.
- User-Friendly Experience: Simple to navigate, making it accessible for those without extensive financial modeling skills.
Who Can Benefit from This Product?
- Individual Investors: Make well-informed choices regarding buying or selling Poly Medicure Limited (POLYMEDNS) shares.
- Financial Analysts: Enhance valuation workflows with comprehensive financial models at your disposal.
- Consultants: Provide clients with swift and accurate professional valuation insights.
- Business Owners: Gain insights into the valuation of major firms like Poly Medicure Limited (POLYMEDNS) to inform your strategic decisions.
- Finance Students: Master valuation methods using authentic data and real-world examples.
Overview of the Template Features
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations for Poly Medicure Limited (POLYMEDNS).
- Real-World Data: Historical and projected financial data for Poly Medicure Limited (POLYMEDNS) preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly financial breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Clear charts and tables designed to present actionable results effectively.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.